Hematological Oncology

SJR Rank #4,361H-index: 59SJR: 1.073Best quartile: Q1APC: US$4,650
Journal website: aims, scope and author guidelines
Publisher

John Wiley and Sons Ltd

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.30.60.91.2

Subject Categories

  • HematologyQ1
  • Medicine (miscellaneous)Q1
  • Cancer ResearchQ2
  • OncologyQ2

Areas: Biochemistry, Genetics and Molecular Biology · Medicine

Most published research topics

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchCNS Lymphoma Diagnosis and TreatmentViral-associated cancers and disordersAcute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchLung Cancer Treatments and MutationsChronic Myeloid Leukemia TreatmentsMultiple Myeloma Research and Treatments

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs090180270360

Documents per Year

2022202504080120160

Detailed Information

ISSN

1099-1069, 0278-0232

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

2.76

References per Document

34.18

Coverage

1983-2026

Scope

Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.

Metrics from SCImago Journal Rank 2025. View on SCImago